comparemela.com

Latest Breaking News On - Astex therapeutics limited - Page 1 : comparemela.com

First Results with Erdafitinib-Releasing Intravesical

Investigational TAR-210 first-in-human results highlight the potential for local sustained release of erdafitinib with a novel intravesical delivery.

Comunidad autonoma de catalunaRegion flamandeIndianj urolJanssen cilag gmbJanssen pharmaceuticaJeffrey infanteMartin vogelUrology care foundationJanssen research developmentNone of the janssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonEuropean society for medical oncologyAstex therapeuticsOncology early clinical developmentTranslational researchAstex announces new drug discovery alliance

Results from Phase 2 THOR-2 Study Showed Improved Rates of

Data from Cohort 1 of the Phase 2 THOR-2 study showed oral erdafitinib reduced the risk of disease recurrence or death compared with intravesical.

Region flamandeUnited kingdomJanssen cilag gmbIndianj urolKiran patelJames wf cattoMartin vogelJanssen pharmaceuticaAstex announces new drug discovery allianceUniversity of sheffieldClinical developmentJanssen researchNone of the janssen pharmaceutical companiesExchange commissionJanssen pharmaceutical companiesDrug administration

Janssen Announces Erdafitinib Improved Overall Survival

Confirmatory data from Cohort 1 of the Phase 3 THOR study showed greater than four-month improvement in median overall survival in patients treated with.

France generalRegion flamandeUnited statesMilenkovic petronicSipetic grujicics urothelialJanssen cilag gmYohann loriotKiran patelInstitut gustave roussyJanssen pharmaceuticaClinical developmentCompanies of johnsonAstex therapeuticsDrug administrationJanssen pharmaceutical companiesJanssen research development in phase

vimarsana © 2020. All Rights Reserved.